Work

Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.tps10066

Authors: Mary Frances Wedekind, Srivandana Akshintala, Brigitte C. Widemann, Charles G. Minard, Olga Militano, David Hall, Zanette Bradley, Joel M. Reid, Joseph Gerald Pressey, Elad Sharon, Elizabeth Fox, Brenda Weigel

Institutions: National Institutes of Health, National Cancer Institute, Baylor College of Medicine, Children's Oncology Group, Children's Hospital Colorado, Mayo Clinic, Cincinnati Children's Hospital Medical Center, St. Jude Children's Research Hospital, University of Minnesota

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379345641

Cites:

Cited by: 1

Related to: 10